Immunological Variables Associated to ICI Toxicity in Cancer Patients
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Melanoma|Non Small Cell Lung Cancer|Non-melanoma Skin Cancer|Gastrointestinal Cancer|Head and Neck Cancer|Renal Cell Carcinoma|Small Cell Lung Cancer|Mesothelioma, Malignant|Bladder Cancer|Merkel Cell Carcinoma|Hepatocellular Carcinoma|MSI-H Colorectal Cancer
Interventions: DRUG: Checkpoint Blockade, Immune
Sponsor: Jules Bordet Institute